You are here
Multi Injection Vial Anti-contamination cap (MIVA-Cap)
Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911SR-22-P-0002
Agency Tracking Number: C212-004-0074
Amount:
$167,470.02
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
CBD212-004
Solicitation Number:
21.2
Timeline
Solicitation Year:
2021
Award Year:
2022
Award Start Date (Proposal Award Date):
2022-02-14
Award End Date (Contract End Date):
2022-08-13
Small Business Information
1225 S Shamrock Ave
Monrovia, CA
91016-4244
United States
DUNS:
168312028
HUBZone Owned:
No
Woman Owned:
No
Socially and Economically Disadvantaged:
No
Principal Investigator
Name: Ricky Whitener
Phone: (626) 381-9974
Email: rwhitener@chromologic.com
Phone: (626) 381-9974
Email: rwhitener@chromologic.com
Business Contact
Name: Naresh Menon
Phone: (626) 381-9974
Email: nmenon@chromologic.com
Phone: (626) 381-9974
Email: nmenon@chromologic.com
Research Institution
N/A
Abstract
To meet CBD’s need for a multi-dose formulation of scopolamine hydrobromide trihydrite ChromoLogic proposes to develop a vial add-on containing a self-decontamination cap with a self-healing material to eliminate evaporation and contamination risks through needle punctures in the septum. CL will also perform forced degradation and stability tests with a panel of preservatives to select optimal preservative/concentration and achieve target shelf-life. Overall, CL plans to work with the CBD to ensure this product is an amendment to their already existing FDA process for approval of their single-dose formulation.
* Information listed above is at the time of submission. *
